AngloGold Ashanti Limited (ADR) (AU) Reaches $10.07 After 4.00% Down Move, Boston Scientific (BSX) Sellers Decreased By 5.35% Their Shorts

June 19, 2017 - By Marguerite Chambers

The stock of AngloGold Ashanti Limited (ADR) (NYSE:AU) is a huge mover today! About 3.41 million shares traded. AngloGold Ashanti Limited (ADR) (NYSE:AU) has declined 18.89% since June 19, 2016 and is downtrending. It has underperformed by 35.59% the S&P500.The move comes after 5 months negative chart setup for the $4.17 billion company. It was reported on Jun, 19 by Barchart.com. We have $9.67 PT which if reached, will make NYSE:AU worth $166.80 million less.

Boston Scientific Corporation (NYSE:BSX) had a decrease of 5.35% in short interest. BSX’s SI was 15.09M shares in June as released by FINRA. Its down 5.35% from 15.95 million shares previously. With 5.58 million avg volume, 3 days are for Boston Scientific Corporation (NYSE:BSX)’s short sellers to cover BSX’s short positions. The SI to Boston Scientific Corporation’s float is 1.11%. About 2.06M shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since June 19, 2016 and is uptrending. It has outperformed by 2.42% the S&P500.

Among 4 analysts covering Anglogold Ashanti Limited (NYSE:AU), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Anglogold Ashanti Limited had 10 analyst reports since August 18, 2015 according to SRatingsIntel. The company was upgraded on Monday, January 18 by Goldman Sachs. The rating was upgraded by Goldman Sachs on Friday, January 15 to “Buy”. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, March 8. The firm earned “Sector Perform” rating on Monday, April 24 by RBC Capital Markets. The stock of AngloGold Ashanti Limited (ADR) (NYSE:AU) earned “Sell” rating by Citigroup on Tuesday, May 10. The firm has “Neutral” rating by Citigroup given on Tuesday, February 23. The stock of AngloGold Ashanti Limited (ADR) (NYSE:AU) earned “Outperform” rating by RBC Capital Markets on Monday, April 11.

AngloGold Ashanti Limited is a gold mining company. The company has market cap of $4.17 billion. The Company’s business activities span the spectrum of the mining value chain. It has a 66.05 P/E ratio. The Company’s main product is gold.

Investors sentiment decreased to 0.84 in 2016 Q4. Its down 0.28, from 1.12 in 2016Q3. It dropped, as 67 investors sold Boston Scientific Corporation shares while 195 reduced holdings. 60 funds opened positions while 161 raised stakes. 1.23 billion shares or 1.80% more from 1.21 billion shares in 2016Q3 were reported. Bridgewater Associates Ltd Partnership invested in 91,000 shares. Robecosam Ag holds 0.81% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 406,444 shares. Beech Hill Advsrs reported 0.29% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Jnba Advsr invested in 7,298 shares or 0.04% of the stock. Aberdeen Asset Pcl Uk has invested 0.08% in Boston Scientific Corporation (NYSE:BSX). Clarivest Asset Limited Co has invested 0.01% in Boston Scientific Corporation (NYSE:BSX). Blackrock Institutional Tru Na reported 37.88 million shares stake. First Personal Finance Services accumulated 9,027 shares. Ibm Retirement Fund reported 126,479 shares. Quantitative Systematic Strategies Limited Liability Company owns 83,517 shares. Mutual Of America Capital Management Limited Liability Com reported 226,139 shares. Voya Inv Mgmt Limited Company invested in 0.52% or 10.16 million shares. Profund Advsr Limited Liability Co accumulated 48,621 shares or 0.05% of the stock. Comerica Bancshares accumulated 357,544 shares or 0.07% of the stock. Moreover, Janus Capital Mngmt Ltd Limited Liability Company has 0.76% invested in Boston Scientific Corporation (NYSE:BSX).

Boston Scientific Corporation is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The company has market cap of $38.64 billion. The Firm offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It has a 90.08 P/E ratio. It operates in three divisions: Cardiovascular, Rhythm Management and MedSurg.

Among 26 analysts covering Boston Scientific Corporation (NYSE:BSX), 20 have Buy rating, 0 Sell and 6 Hold. Therefore 77% are positive. Boston Scientific Corporation had 39 analyst reports since July 27, 2015 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Thursday, April 28. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by RBC Capital Markets on Tuesday, May 30. The company was initiated on Thursday, June 9 by Guggenheim. Argus Research upgraded the stock to “Buy” rating in Thursday, September 1 report. As per Thursday, April 28, the company rating was maintained by Wedbush. Needham maintained the stock with “Buy” rating in Friday, February 3 report. The firm earned “Outperform” rating on Friday, June 9 by RBC Capital Markets. As per Tuesday, September 22, the company rating was initiated by UBS. The firm earned “Hold” rating on Monday, May 1 by Oppenheimer. As per Wednesday, October 28, the company rating was maintained by Needham.

Since January 9, 2017, it had 0 buys, and 20 selling transactions for $10.61 million activity. On Tuesday, February 28 Mirviss Jeffrey B. sold $616,663 worth of Boston Scientific Corporation (NYSE:BSX) or 25,000 shares. Pierce David A sold $82,313 worth of Boston Scientific Corporation (NYSE:BSX) on Thursday, June 1. Another trade for 4,832 shares valued at $120,034 was sold by Pratt Timothy A.. Shares for $592,858 were sold by Thepaut Eric Francis Yves on Monday, February 6. Dawkins Keith D had sold 80,783 shares worth $2.04M on Tuesday, February 7. The insider Phalen Michael P. sold 79,045 shares worth $1.94M. $754,454 worth of stock was sold by Ballinger Kevin J. on Wednesday, May 17.